Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

pembrolizumab

  • You have access
    Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
    TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA
    Anticancer Research June 2023, 43 (6) 2717-2724; DOI: https://doi.org/10.21873/anticanres.16438
  • You have access
    Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature
    LUKAS CHINCZEWSKI, FELIX WILHELM FELDHAUS, WOLFGANG SCHMITT, IOANA BRAICU, EVA ROSER and JALID SEHOULI
    Anticancer Research April 2023, 43 (4) 1655-1662; DOI: https://doi.org/10.21873/anticanres.16317
  • Open Access
    Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
    GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE
    Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
  • Open Access
    Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
    SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER
    Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
  • You have access
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
    JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG
    Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
  • You have access
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
    IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
  • Open Access
    Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan
    DAISUKE SANO, MOTOHIKO TOKUHISA, HIDEAKI TAKAHASHI, TAKASHI HATANO, GOSHI NISHIMURA, YASUSHI ICHIKAWA and NOBUHIKO ORIDATE
    Anticancer Research September 2022, 42 (9) 4477-4484; DOI: https://doi.org/10.21873/anticanres.15948
  • You have access
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
    TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA
    Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
  • You have access
    Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer
    MOTOHIRO FUJIWARA, RYO FUJIWARA, TETSUYA URASAKI, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA
    Anticancer Research April 2022, 42 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.15685
  • You have access
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
    IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638

Pages

  • Next
  • 1
  • 2
  • 3
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire